Regarding the individual outcome of MACEs, serum RBP4 level was significantly associated with an increased risk of HR (1.18, 95% CI: 1.02–1.38) and showed a trend to increase the risk of acute coronary syndrome, stroke, peripheral vascular disease, and cardiovascular death, despite failing to reach statistical significance (Supplementary Figure 2). Here, RBP4 is linked to acute coronary syndrome.